

Market Announcement

31 July 2025

Imagion Biosystems Limited (ASX: IBX) – Trading Halt

Trading in the securities of Imagion Biosystems Limited ('IBX') will be halted at the request of IBX, pending the release of an announcement by IBX.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Monday, 4 August 2025; or
- the release of the announcement to the market.

IBX's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

IMAGION BIOSYSTEMS LIMITED

ASX: IBX

31 July 2025

Adviser, Listings Compliance (Sydney)
ASX Compliance Pty Limited
20 Bridge Street,
Sydney, NSW 2000

By email only: tradinghaltssydney@asx.com.au

REQUEST FOR TRADING HALT

Imagion Biosystems Limited (ASX: IBX) (the Company) requests an immediate halt to the trading of the Company's securities quoted on the Australian Securities Exchange (ASX) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending the release of information by the Company to the market relating to a capital raising through lead manager CPS Capital ("purpose").

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make a material announcement to the market in relation to the stated purpose above.
2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on 4 August 2025, or when the announcement regarding the stated purpose is released to the market.
3. The Company expects to make the announcement to the market before the commencement of normal trading on Monday 4 August 2025.
4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

Yours sincerely

A handwritten signature in black ink, appearing to read "Melanie Leydin".

Melanie Leydin
Director and Company Secretary

Imagion Biosystems Limited

ASX: IBX ACN 616 305 027

Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000

<http://www.imagionbiosystems.com/> | investor@imagionbio.com

